Innovations in High Blood Pressure Intervention Benefit Patients with Resistant Hypertension
World Hypertension Day's focus on High Blood Pressure Awareness, Management and Control highlights Importance of New Therapies, like Ultrasound Renal Denervation from Recor Medical
PALO ALTO, Calif., FRANKFURT, Germany, May 17, 2025 /PRNewswire/ -- May 17, 2025, is World Hypertension Day, a day dedicated to raising awareness about high blood pressure, also known as the "silent killer" because many people do not know they have it and, over time, it can lead to serious health issues. The theme of World Hypertension Day, "Measure Your Blood Pressure Accurately, Control It, Live Longer!" highlights the importance of not only awareness but also accurate monitoring, diagnosis, and treatment of hypertension.
According to a report from the World Health Organization, the number of adults with hypertension doubled between 1990 and 2019 from 650 million to 1.3 billion. The report also states that only 54 percent of adults with hypertension are diagnosed and only 42 percent receive treatment. And recent studies1,2 have suggested that BP assessment in the clinical setting can often get a hypertension diagnosis wrong or miss it completely. Left undetected or uncontrolled, hypertension is a leading contributor to serious health risks, including heart attack, stroke and kidney disease, making accurate diagnosis, monitoring and treatment of the condition critical.
About one-third of the patients who are treated for hypertension remain uncontrolled despite making healthy lifestyle changes and taking more than three medications. For these patients, innovation and investment in new solutions are vital to achieve blood pressure control and realize a healthier future. From pharmaceutical treatments to technology, patients need new therapies that can provide life-changing results. This includes medical device-based therapies, like the Paradise™ Ultrasound Renal Denervation (uRDN) system, an additional treatment option for patients who remain uncontrolled and at elevated cardiovascular risk despite standard lifestyle changes and treatment with oral medications.
The Paradise uRDN system is a first-of-its-kind ultrasound-based RDN technology designed to lower blood pressure by denervating the sympathetic nerves surrounding the renal arteries, reducing the overactivity that can lead to hypertension. The Paradise uRDN system delivers two to three doses of 360-degree ultrasound energy — lasting seven seconds each — through the main renal arteries to the surrounding nerves.* The Paradise catheter features the exclusive HydroCooling™ system, which circulates sterile water through the balloon catheter during the procedure to help protect the renal artery wall. This minimally invasive procedure is supported by many medical societies including the American Heart Association, the American College of Cardiology, the European Society of Cardiology and others.
"Taking a risk-based approach to hypertension makes sense and this is why the medical societies are increasingly behind it," said Prof. Andrew Sharp, University College Dublin and The Mater Misericordiae Hospital, Dublin, Ireland. "Blood pressure reductions of just 5 to 10mmHg can have a significant impact on the risk of cardiovascular complications, such as stroke and heart attack, but gain is greatest in those who are most at risk, such as patients who also have other risk factors for cardiovascular health such as diabetes. Early blood pressure control may also limit the vascular aging process and yet over half of patients worldwide are not even at the basic standard of control of 140/90mmHg. With guidelines now suggesting lower BP targets of 130/80 for many, new treatments in this space are welcome. Renal denervation is a recently approved tool to safely aid in blood pressure lowering throughout the 24-hour cycle and is independent of patient adherence to medication. The procedure shows an excellent safety profile and typically takes under an hour to perform, with lasting BP reductions demonstrated."
Recor Medical – the manufacturer of the Paradise System - has been focused on developing and testing uRDN for the treatment of hypertension since 2009, and completed three independently powered, sham-controlled, randomized clinical trials, all which demonstrate the efficacy and safety of the Paradise System. Recor has also initiated the US Global Paradise System (GPS) Post-Approval Study to collect real-world clinical evidence with long-term follow-up in 1,000 patients with uncontrolled hypertension in the United States.
The Paradise uRDN system is indicated to reduce blood pressure as an adjunctive treatment in hypertension patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. A physician will make a medical assessment to determine if a patient is a candidate for ultrasound renal denervation. The most common risks include pain, vascular access site complications and vasospasm. Full important risk information can be viewed here.
*Anatomies vary. See Paradise IFU for treatment strategies.
Liu H et al.: Arm Position and Blood Pressure Readings. The ARMS Crossover Randomized Clinical Trial. JAMA Intern Med. 2024;184(12):1436-1442. doi:10.1001/jamainternmed.2024.5213
https://newsroom.heart.org/news/high-blood-pressure-while-lying-down-linked-to-higher-risk-of-heart-health-complications
About Recor Medical, Inc.Recor Medical, headquartered in Palo Alto, Calif., a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., is a medical technology company focused on transforming the management of hypertension. Recor has pioneered the use of the Paradise Ultrasound Renal Denervation system for the treatment of hypertension. The Paradise uRDN system is an investigational device in Japan, is FDA approved in the United States, and bears the CE mark. Recor has reported positive outcomes in three independent, randomized, sham-controlled studies of the Paradise uRDN system in patients with mild-to-moderate and resistant hypertension. In addition, Recor is conducting the Global Paradise System ("GPS") Registry in the European Union and the UK, and has initiated the US GPS post-approval study in the United States.http://www.recormedical.com/
About Otsuka Medical Devices Co., Ltd.Otsuka Medical Devices Co., Ltd. engages in the global development and commercialization of medical devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment. Otsuka Medical Devices is a subsidiary of Otsuka Holdings Co., Ltd. (www.otsuka.com/en), a global healthcare company listed on the Tokyo Stock Exchange (JP 4578).
https://www.omd.otsuka.com/en/
Photo: https://mma.prnewswire.com/media/2689174/RecorMedical_BP_Measure.jpgLogo: https://mma.prnewswire.com/media/2689173/Recor_Medical_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/innovations-in-high-blood-pressure-intervention-benefit-patients-with-resistant-hypertension-302457998.html
SOURCE Recor Medical Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
3 hours ago
- CBS News
Lifelong Phillies fan in need of kidney transplant making pitch to Philadelphia to help save his life
One lifelong Philadelphia Phillies fan is making a pitch to the city to help save his life. AJ Tantala, a 25-year-old from Langhorne, Pennsylvania, is hoping people look up and feel inspired to go to bat for him. Tantala has two big passions in life: theater and the Phillies. "I just had this attitude growing up, 'Oh, it's not for me, you can't do that, it's not cool,'" Tantala said. "Later in high school, I got involved in it, and it was one of the most rewarding experiences." "He was born, and I knew from Day 1 that he would be involved in theater arts," Penny Tantala, AJ's mother, said. "I knew it." AJ Tantala even found a way to merge his passions in a Cinderella play. AJ Tantala "I turned around, did a big reveal, and there was my Phillies jersey," he said. "I think it was the biggest standing ovation of the show." Beneath his well-versed life lies enormous health issues. Born with posterior urethral valve syndrome, he suffered from kidney failure when he was 2 years old, with an emergency surgery resulting in kidney disease. "Why can't it be me and not him?" Penny Tantala said. "You never want to see your kids hurt in any way." "For the first 22 years of my life, I was just naive to it," AJ Tantala said. "I was ignoring it." He was no longer able to ignore it about three years ago when his condition worsened. His kidney function was plummeting to about 10%, making the need for a transplant inevitable. "We've had 19 different people come forward and try to be donors for him," Penny Tantala said. "There's some small medical condition that would prohibit them from being a donor." In his urgent search for a kidney donor, AJ Tantala has placed six billboards across the Delaware Valley, featuring the Phillies' font and a photo of himself at opening day. CBS News Philadelphia "I love the Phillies. I know so many people out there do too," AJ Tantala said. "I thought if I went that route, it wouldn't just reach more people but the hearts of a lot more people." A kidney donor would not only give a vital organ but also a chance at his biggest dream: a normal life with the ones he loves. AJ Tantala is recently engaged to a teacher who also loves theater, but he hasn't been able to perform for over two years now.
Yahoo
6 hours ago
- Yahoo
Multi-Blood Monitoring System Market is expected to reach USD 3.9 billion by 2034, with a 6.4% CAGR growth
Multi Blood Monitoring System Market Overview 2025-2034 Luton, Bedfordshire, United Kingdom, June 10, 2025 (GLOBE NEWSWIRE) -- The global multi blood monitoring system market is witnessing dynamic expansion, with its value estimated at approximately USD 2.1 billion in 2024, and expected to grow to around USD 3.9 billion by 2034. This translates into a Compound Annual Growth Rate (CAGR) of 6.4% over the forecast period from 2025 to 2034. This growth is primarily fueled by the increasing demand for accurate, efficient, and accessible blood monitoring technologies across various healthcare applications. Download PDF Brochure: These devices are critical in the management of chronic diseases such as diabetes and cardiovascular conditions. As the global burden of such illnesses escalates, particularly among aging populations and across developing regions, the need for real-time, portable, and user-friendly blood monitoring systems has become more urgent than ever. Market Drivers and Opportunities Several underlying factors are contributing to the expansion of this market. Among the most significant drivers is the rising prevalence of chronic diseases. The World Health Organization (WHO) forecasts that by 2030, chronic diseases will account for over 75% of global deaths, highlighting the growing necessity for continuous and reliable health monitoring tools. Moreover, technological advancements in wearable devices, mobile health apps, and telemedicine have revolutionized the way blood monitoring is conducted. These innovations have led to more personalized and preventive healthcare solutions, allowing patients to self-monitor in real-time, often without the need for clinical supervision. This trend is particularly appealing to tech-savvy consumers and younger demographics who are increasingly proactive about their health. Emerging economies also present significant growth potential. With rising healthcare expenditure, expanding middle-class populations, and improving medical infrastructure, regions such as Asia-Pacific, Latin America, and parts of the Middle East are becoming fertile grounds for market expansion. Additionally, the integration of AI and machine learning into monitoring systems is creating opportunities for predictive diagnostics and tailored treatment strategies, revolutionizing the future of personalized medicine. Key Market Challenges Despite its positive growth outlook, the multi blood monitoring system market faces certain challenges. One of the primary obstacles is the complex regulatory landscape. Medical device manufacturers must navigate stringent approval processes, especially in developed regions like North America and Europe. These regulations, although necessary for ensuring safety and efficacy, often delay product rollouts and increase development costs. Supply chain disruptions have also impacted the market, particularly during and after the COVID-19 pandemic. Delays in procuring raw materials, component shortages, and transportation hurdles have affected production timelines and product availability. Furthermore, high costs associated with technologically advanced blood monitoring devices can be a deterrent for adoption, especially in price-sensitive markets. Healthcare providers are often pressured to deliver cost-effective solutions, which can limit investments in premium monitoring systems. Another pressing concern is data security and patient privacy. With the growing digitalization of healthcare and increased reliance on cloud-based data storage, ensuring the protection of sensitive patient information has become paramount. Regulatory frameworks such as HIPAA and GDPR are placing additional burdens on companies to fortify their cybersecurity measures. Market Segmentation Analysis By Product Type The market is segmented into several product categories including continuous glucose monitoring (CGM) systems, blood pressure monitors, cholesterol testing devices, and complete blood count (CBC) test devices. Among these, CGM systems are emerging as the dominant product category, accounting for roughly 35% of market share. The increased prevalence of diabetes globally has significantly contributed to this trend. Blood pressure monitoring devices come in second, capturing an estimated 25% of the market, owing to the widespread incidence of hypertension. Cholesterol testing devices follow with a 15% market share, as more individuals become aware of the risks associated with high cholesterol levels. By End User Hospitals are the largest consumers of multi blood monitoring systems, accounting for nearly 45% of the market share. The growing number of patients and a strong focus on preventive healthcare are driving demand in this segment. Diagnostic laboratories represent the second-largest user group, contributing 30% of market revenue, largely due to the complexity and volume of testing they handle. Homecare settings have gained traction, especially post-pandemic, and currently hold around 20% of the market. The convenience of remote monitoring has been widely appreciated, particularly among the elderly and chronically ill patients who prefer in-home testing. By Technology From a technology standpoint, wearable technologies are transforming the landscape, projected to represent 40% of the market by 2034. These devices offer unmatched convenience and user engagement. Invasive technologies still maintain a solid 45% market share, particularly in clinical environments where precision is critical. Meanwhile, non-invasive technologies are growing steadily and are expected to hold 15% of the market, driven by advancements in optical and sensor-based innovations. By Application Diabetes management remains the top application area, constituting about 50% of the total market. As diabetes rates continue to climb worldwide, the demand for continuous and accurate glucose monitoring devices is increasing proportionally. Cardiovascular monitoring is another important application, making up 30% of the market, while fitness and wellness monitoring is growing rapidly, accounting for around 15% as consumers adopt proactive health strategies. By Distribution Channel In terms of distribution, offline sales still dominate with a 55% market share, primarily due to the preference for in-person consultations and product demonstrations in hospital and clinical settings. Online channels, however, are growing fast and now represent 30% of sales, fueled by digital adoption and e-commerce growth. Direct sales—through specialized distributors—comprise the remaining 15%, ensuring product customization and support services. Browse full Report - Market Segmentation Product Type - Continuous Glucose Monitoring Systems - Blood Pressure Monitoring Devices - Cholesterol Testing Devices - Complete Blood Count Test Devices - Others End-User - Hospitals - Diagnostic Laboratories - Homecare Settings - Research Institutions Technology - Wearable Technology - Non-invasive Technology - Invasive Technology Application - Diabetes Management - Cardiovascular Monitoring - Blood Disorders Management - Fitness and Wellness Monitoring Distribution Channel - Online Sales - Offline Sales - Direct Sales Region - North America - Europe - Asia Pacific - Latin America - Middle East & Africa Regional Outlook Regionally, North America leads the global market, accounting for approximately 40% of total revenues in 2024. This dominance is attributed to advanced healthcare infrastructure, favorable regulatory support, and the presence of leading industry players. Europe follows with a 30% market share, supported by robust public healthcare systems and a rising focus on personalized medicine. The Asia-Pacific region is the fastest-growing market, projected to expand at a CAGR of 7.5%. This growth is driven by large patient populations, increasing disposable income, and government initiatives to enhance healthcare access. Countries such as China, India, and Japan are key contributors to this growth trajectory. Latin America and the Middle East & Africa collectively account for a modest share (5% in 2024) but are poised for steady growth due to improvements in healthcare infrastructure and expanding awareness about chronic disease management. Key Competitors Abbott Laboratories Roche Holding AG Siemens Healthineers Becton, Dickinson and Company (BD) Medtronic plc Nova Biomedical Johnson & Johnson Dexcom, Inc. Arkray, Inc. Ascensia Diabetes Care Terumo Corporation GlySens Incorporated Insulet Corporation Elysium Health LabCorp Recent Industry Developments Several companies have made notable strides in advancing this market: Abbott Laboratories launched FreeStyle Libre 3, a real-time glucose monitor with a discreet sensor, in June 2023, strengthening its lead in the CGM space. In April 2023, Roche formed a strategic partnership with a wearable tech firm to integrate blood monitoring devices with smart devices, enhancing patient engagement and adherence. Siemens Healthineers acquired an AI-based diagnostics company in August 2023, signaling a deeper focus on precision diagnostics through data analytics. Dexcom received FDA approval in September 2023 for a no-fingerstick CGM device, which is likely to broaden its user base and redefine market standards. Medtronic expanded its product line into Asia and Africa in July 2023, targeting underserved markets and accelerating growth in emerging economies. This report is also available in the following languages : Japanese (マルチ血液モニタリングシステム市場), Korean (다혈액 모니터링 시스템 시장), Chinese (多血液监测系统市场), French (Marché des systèmes de surveillance sanguine multi-sang), German (Markt für Multi-Blutüberwachungssysteme), and Italian (Mercato dei sistemi di monitoraggio multi-sangue), etc. Request Sample Pages: More Research Finding – Medical Refrigerated Market The global medical refrigerated market is valued at approximately $6.5 billion in 2024, with projections indicating a potential increase to around $10 billion by 2034. This growth reflects a robust Compound Annual Growth Rate (CAGR) of approximately 4.5% during the forecast period from 2025 to 2034. Cardiovascular Monitoring Devices Market The cardiovascular monitoring devices market is valued at approximately $10.5 billion in 2024, with projections indicating substantial growth, reaching around $16.8 billion by 2034. This translates to a robust Compound Annual Growth Rate (CAGR) of approximately 4.8% during the forecast period from 2025 to 2034. Non Invasive Hemodynamic Detection System Market The global Non-Invasive Hemodynamic Detection System market is valued at approximately USD 2.1 billion in 2024, with strong growth anticipated over the next decade. By 2034, the market is projected to reach around USD 4.5 billion, representing a Compound Annual Growth Rate (CAGR) of approximately 8.0%. Disposable Syringes and Accessories Market The global disposable syringes and accessories market is valued at approximately $7.5 billion in 2024, with a projected growth trajectory that anticipates reaching around $13 billion by 2034. This translates to a compound annual growth rate (CAGR) of about 6.1% over the 2025-2034 period. Blood Collection Mixer Market The blood collection mixer market is valued at approximately $250 million in 2024 and is projected to reach around $400 million by 2034. This growth represents a Compound Annual Growth Rate (CAGR) of about 5.1% during the forecast period from 2025 to 2034. Hemochromatosis Treatment Market The global hemochromatosis treatment market is valued at approximately $2.1 billion in 2024. The market is anticipated to grow significantly, reaching an estimated $3.5 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of 5.2% during the forecast period of 2025–2034. Gestational Trophoblastic Disease Market The gestational trophoblastic disease (GTD) market is currently valued at approximately $1.8 billion in 2024, with projections indicating a potential growth to around $3.1 billion by 2034. This represents a compound annual growth rate (CAGR) of approximately 6.2% during the forecast period from 2025 to 2034. Septicemia Diagnostic Market The global septicemia diagnostics market is valued at approximately $1.5 billion in 2024, with projections indicating a growth to around $2.9 billion by 2034. This represents a Compound Annual Growth Rate (CAGR) of about 7.5% for the period from 2025 to 2034. Single Use Safety Lancet Market The global market for single-use safety lancets, valued at approximately $1.2 billion in 2024, is expected to reach around $2.5 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of 7.7% during the forecast period from 2025 to 2034. Microalbuminuria Test Strip Market The microalbuminuria test strip market is poised for notable growth, valued at approximately $1.2 billion in 2024. This market is projected to expand to around $2.4 billion by 2034, indicating a robust growth trajectory. The Compound Annual Growth Rate (CAGR) for the forecast period from 2025 to 2034 is estimated at 7.3%. Monkeypox Virus Detection Reagent Market The monkeypox virus detection reagent market is anticipated to reach approximately $150 million in value by 2024, driven by heightened awareness and diagnostic needs amid ongoing public health surveillance. The market is projected to expand significantly, reaching an estimated $300 million by 2034, reflecting sustained interest in infectious disease diagnostics and preparedness. Blood Tester Market The global blood testing market is anticipated to reach a value of approximately $75 billion in 2024, driven by increasing prevalence of chronic diseases, rising health awareness, and advancements in diagnostic technologies. The market is projected to grow at a Compound Annual Growth Rate (CAGR) of 6.5% from 2025 to 2034, potentially reaching over $135 billion by 2034. HBsAg ELISA Test Kit Market The HBsAg ELISA Test Kit market is poised for robust growth, with a current market value estimated at approximately $1.5 billion in 2024. Driven by the increasing global prevalence of Hepatitis B, ongoing advancements in diagnostic technologies, and rising healthcare expenditures, the market is projected to reach around $2.8 billion by 2034. This trajectory indicates a Compound Annual Growth Rate (CAGR) of approximately 6.5% from 2025 to 2034. Blood Plasma Extractor Market The global blood plasma extractor market is valued at approximately $1.2 billion, driven by rising demand for plasma-derived therapies in treating various diseases. The market is projected to reach about $2.9 billion by 2034, reflecting an impressive Compound Annual Growth Rate (CAGR) of approximately 9.2% from 2025 to 2034. Amphetamine Test Kit Market The amphetamine test kit market is projected to reach a value of approximately $500 million in 2024, with expectations to grow to around $900 million by 2034. This growth reflects a robust Compound Annual Growth Rate (CAGR) of 6% during the forecast period of 2025 to 2034. CONTACT: Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@ in to access your portfolio
Associated Press
11 hours ago
- Associated Press
Bujar Bukoshi, Kosovo independence leader, dies at 78
PRISTINA, Kosovo (AP) — Bujar Bukoshi, a former Kosovo independence leader who for years headed a self-proclaimed government-in-exile, died early Tuesday morning after a long illness, his family said. He was 78. He died in Germany, where he was being treated for cancer and receiving financial support from the Albanian government, according to his family. Kosovo's President Vjosa Osmani expressed deep regret for the loss of 'a visionary physician and a statesman of unparalleled dedication.' 'Dr. Bukoshi, former Prime Minister in Exile, will forever be remembered for his contributions to strengthening the cause of a free and independent Kosovo in the most difficult times for our people,' she wrote in a letter of condolence to his family. A respected physician and surgeon, Bukoshi helped to found the Democratic League of Kosovo, or LDK, in 1989 alongside Ibrahim Rugova, who was later president of Kosovo. Shortly after receiving his medical degree at Belgrade's Medical School University, Bukoshi went into exile, where he raised funds to run parallel governing institutions to peacefully defy the late Yugoslav President Slobodan Milosevic's repressive rule in Kosovo, a former Serbian province. Bukoshi served as prime minister of Kosovo's government in exile from 1991 through 1999, the end of the 1998-1999 war that left around 11,400 people dead. A 78-day NATO air campaign stopped the Serb forces' crackdown on ethnic Albanians and pushed Serbian forces and authorities out of Kosovo. He also led an ethnic Albanian militia that was seen as a rival to the more militant Kosovo Liberation Army. The shadow government, which was never recognized by Belgrade, was formally dissolved in 2000. After the war, Bukoshi served as deputy prime minister, healthcare minister and lawmaker. 'His life and activity are a record of patriotic commitment and unshakable political involvement for Kosovo's freedom and independence,' said LDK's current leader Lumir Abdixhiku. 'His contribution at the most difficult moments of our country will be forever valued.' Kosovo declared independence from Serbia in 2008. Most Western nations recognize its sovereignty, but Serbia and its allies Russia and China don't. Bukoshi was born in Suhareke, 60 kilometers north of the capital Pristina. He is survived by his spouse Zana, three daughters and two nephews. ___ Semini reported from Tirana, Albania.
